Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

TELA Bio, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MALVERN, PA., OCT. 09, 2025 (GLOBE NEWSWIRE) -- TELA BIO, INC. (TELA BIO) (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THE APPOINTMENT OF BETTY JO ROCCHIO, DNP, RN, CRNA, CENP, EBP-C, TO ITS BOARD OF DIRECTORS, AND THE DEPARTURE OF LISA COLLERAN, WHO HAS STEPPED DOWN FOLLOWING FIVE YEARS OF SERVICE ON THE BOARD.

TELA BIO ANNOUNCES ADDITION OF BETTY JO ROCCHIO TO BOARD OF DIRECTORS AND THE DEPARTURE OF DIRECTOR LISA COLLERAN

MALVERN, PA., AUG. 11, 2025 (GLOBE NEWSWIRE) -- TELA BIO, INC. ("TELA BIO"), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025.

TELA BIO REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

MALVERN, PA., AUG. 08, 2025 (GLOBE NEWSWIRE) -- TELA BIO, INC. ("TELA BIO") (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF TELA BIO APPROVED INDUCEMENT GRANTS OF RESTRICTED STOCK UNITS COVERING 10,200 SHARES OF ITS COMMON STOCK TO FOURTEEN NEWLY-HIRED EMPLOYEES, WITH A GRANT DATE OF AUGUST 5, 2025 (THE "GRANT DATE"). THE RESTRICTED STOCK UNITS WERE GRANTED PURSUANT TO THE NASDAQ RULE 5635(C)(4) INDUCEMENT GRANT EXCEPTION AS A COMPONENT OF EACH INDIVIDUAL'S EMPLOYMENT COMPENSATION AND WERE GRANTED AS AN INDUCEMENT MATERIAL TO HIS OR HER ACCEPTANCE OF EMPLOYMENT WITH TELA BIO.

TELA BIO ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

MALVERN, PA., JULY 23, 2025 (GLOBE NEWSWIRE) -- TELA BIO, INC. (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE CANACCORD GENUITY 45TH ANNUAL GROWTH CONFERENCE.

TELA BIO TO PARTICIPATE IN THE CANACCORD GENUITY 45TH ANNUAL GROWTH CONFERENCE

MALVERN, PA., JULY 21, 2025 (GLOBE NEWSWIRE) -- TELA BIO, INC. ("TELA BIO") (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THAT THE COMPANY WILL REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON MONDAY, AUGUST 11, 2025. TELA BIO'S MANAGEMENT WILL HOST A CONFERENCE CALL AND WEBCAST AT 4:30 P.M. ET THAT DAY TO DISCUSS THE FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE.

TELA BIO TO ANNOUNCE SECOND QUARTER 2025 FINANCIAL RESULTS

MALVERN, PA., JUNE 06, 2025 (GLOBE NEWSWIRE) -- TELA BIO, INC. ("TELA BIO") (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS THAT OPTIMIZE CLINICAL OUTCOMES BY PRIORITIZING THE PRESERVATION AND RESTORATION OF THE PATIENT'S OWN ANATOMY, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF TELA BIO APPROVED INDUCEMENT GRANT OF AN OPTION TO PURCHASE 75,000 SHARES OF ITS COMMON STOCK AND RESTRICTED STOCK UNITS COVERING 30,000 SHARES OF ITS COMMON STOCK TO JIM HAGEN, THE COMPANY'S SENIOR VICE PRESIDENT  STRATEGIC COMMERCIAL OPERATIONS, WITH A GRANT DATE OF JUNE 2, 2025 (THE "GRANT DATE"). THE EQUITY AWARDS WERE GRANTED PURSUANT TO THE NASDAQ RULE 5635(C)(4) INDUCEMENT GRANT EXCEPTION AS A COMPONENT OF MR. HAGEN'S EMPLOYMENT COMPENSATION AND WERE GRANTED AS AN INDUCEMENT MATERIAL TO HIS ACCEPTANCE OF EMPLOYMENT WITH TELA BIO.

TELA BIO ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

BASED ON MARKET RESEARCH, INGUINAL HERNIA REPAIR IS THE MOST COMMON TYPE OF HERNIA REPAIR BASED ON MARKET RESEARCH, INGUINAL HERNIA REPAIR IS THE MOST COMMON TYPE OF HERNIA REPAIR

TELA BIO ANNOUNCES EUROPEAN COMMERCIAL LAUNCH OF OVITEX INGUINAL FOR ROBOTIC AND LAPAROSCOPIC INGUINAL HERNIA REPAIR

COMPANY FURTHER STRENGTHENS EXECUTIVE LEADERSHIP TEAM TO DRIVE NEXT PHASE OF GROWTH COMPANY FURTHER STRENGTHENS EXECUTIVE LEADERSHIP TEAM TO DRIVE NEXT PHASE OF GROWTH

TELA BIO APPOINTS JEFFREY BLIZARD AS PRESIDENT

MALVERN, PA., MAY 22, 2025 (GLOBE NEWSWIRE) -- TELA BIO, INC. (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE 2025 JEFFERIES GLOBAL HEALTHCARE CONFERENCE.

TELA BIO TO PARTICIPATE IN THE 2025 JEFFERIES GLOBAL HEALTHCARE CONFERENCE

MALVERN, PA., MAY 09, 2025 (GLOBE NEWSWIRE) -- TELA BIO, INC. ("TELA BIO") (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF TELA BIO APPROVED INDUCEMENT GRANTS OF RESTRICTED STOCK UNITS COVERING 6,600 SHARES OF ITS COMMON STOCK TO TWELVE NEWLY-HIRED EMPLOYEES, WITH A GRANT DATE OF MAY 5, 2025 (THE "GRANT DATE"). THE RESTRICTED STOCK UNITS WERE GRANTED PURSUANT TO THE NASDAQ RULE 5635(C)(4) INDUCEMENT GRANT EXCEPTION AS A COMPONENT OF EACH INDIVIDUAL'S EMPLOYMENT COMPENSATION AND WERE GRANTED AS AN INDUCEMENT MATERIAL TO HIS OR HER ACCEPTANCE OF EMPLOYMENT WITH TELA BIO.

TELA Bio, Inc.

TELA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TELA Bio, Inc.

TELA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TELA